This content is machine translated GLP-1 receptor agonists Jack of all trades in the fight against type 2 diabetes GLP-1 receptor agonists (RA) have been used in the treatment of diabetic patients since 2005. For patients, their introduction was a milestone, as GLP-1 RAs have the great advantage of…
View Post 5 min This content is machine translated Type 2 diabetes mellitus Heart and kidney protected in different patient groups Approximately 40% of patients with type 2 diabetes mellitus (T2DM) develop diabetic kidney disease, which contributes to increased cardiovascular and mortality risk [1, 2]. This makes it all the more…
View Post 3 min This content is machine translated Type 1 diabetes Despite known cardiac risk, many patients are undertreated Cardiac problems such as coronary artery disease and heart failure are among the most common and dangerous complications of type 1 diabetes. The mortality risk is significantly increased. Although this…
View Post 4 min This content is machine translated Diabetes Cases Type 2 diabetes mellitus and marked obesity A 48-year-old, severely obese patient is diagnosed with full-blown metabolic syndrome during an operative evaluation of osteoarthritis of the upper ankle. His arterial hypertension, dyslipidemia, hyperuricemia, grade III obesity, and…
View Post 7 min This content is machine translated Diabetes Management Nephro- and cardioprotection as an interdisciplinary challenge Early detection and treatment of renal dysfunction and cardiovascular risk factors in type 2 diabetes mellitus is essential. Experts see a need for action in this area, especially with regard…
View Post 6 min This content is machine translated RA therapy Let’s talk about JAKs The treatment of rheumatoid arthritis (RA) has made great progress over the past 20 years. This relates both to the range of drugs available and to developments in terms of…
View Post 4 min This content is machine translated Diabetes mellitus type 2 New Swiss guidelines support cardiovascular disease control The treatment of type 2 diabetes mellitus has undergone a transformation in recent years with the approval of new drug classes. The focus is no longer on pure glycemic control,…
View Post 4 min This content is machine translated Diabetes Cases Cardio-renal prevention: the revolution in diabetes management in 2020 A 68-year-old patient with type 2 diabetes mellitus is undergoing cardiac rehabilitation after a myocardial infarction. Despite antidiabetic treatment, his HbA1c value is deteriorating and his weight is steadily increasing. However, with the…
View Post 3 min This content is machine translated Diabetic kidney disease Canagliflozin approved in fast track for diabetic nephropathy Kidney protection is extremely important for diabetes sufferers. Recently, canagliflozin became the first SGLT-2 inhibitor in Switzerland to receive a marketing authorization extension to reduce the risk of progression to…
View Post 3 min This content is machine translated Heart failure in type 2 diabetes Indication expansion for SGLT2 inhibitor and combination preparation Because of the high prevalence and mortality, it is particularly important to protect patients with type 2 diabetes from heart failure as early as possible. The indication expansion of dapagliflozin…
View Post 6 min This content is machine translated Type 2 diabetes: SGED Recommendations 2020 Update Cardiovascular risk stratification and personalized therapy. When prescribing antidiabetic therapy, other criteria are relevant today in addition to blood glucose control. The cardiac benefit of SGLT2 inhibitors and GLP1 analogues has been incorporated into international guidelines…
